Levels of Visfatin/NAMPT in Human Milk
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: observational study.
- Who it may be relevant to
- Registry conditions: Visfatin Levels in Maternal Milk Samples, Birth Weight. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Italy
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Levels of Visfatin/NAMPT in Human Milk.VISFAMILK
Overview
Visfatin, released in maternal milk at different concentrations related to the maternal conditions, could act as a biomarker with a prognostic/predictive value to determine different newborn clinical conditions, particularly the weight loss of the neonate.
Detailed description
The aim of the study is to analyse a retrospective cohort of well characterized mothers in their post-partum period, and to measure Visfatin levels through collection of maternal milk samples. They will be collected in three different moments after the birth (48 hours, 7 days and 30 days) and Visfatin levels will be analysed through an ELISA kit Adipogen. In parallel, the levels of Visfatin will be evaluated in the maternal plasma/serum collected after 1-2 days postpartum.
Lastly, correlations between Visfatin levels and biological/clinical features of mothers and newborns will be explored.
Interventions
- Other observational study
observational study
Primary outcome measures
- Visfatin levels [Time frame: 48 hours, 7 days and 30 days]
- Visfatin levels [Time frame: 1-2 days post-partum]
Secondary outcome measures (2)
- values of Visfatin [Time frame: 6 months]
- values of Visfatin [Time frame: 6 months]
Eligibility criteria
Inclusion criteria
- Healthy male and female infants born after 37 weeks' gestation who do not have conditions related to congenital abnormalities
- Maternal hospitalization
- Acquisition of the informed consent form signed by the patient
Exclusion criteria
- Refusal of the patient to participate in the study
- Presence of hypogalactia or agalactia in the patient
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Italy · 1 center
- Ospedale degli Infermi - ASL BI — Ponderano
Identifiers
NCT: NCT06487286 · 4